Craig Mayer, Nick WIlliams, Vojtech Huser
Lister Hill National Center for Biomedical Communications, National Library of Medicine, NIH, Bethesda, MD

See the full regCTG repository at https://github.com/lhncbc/CRI/tree/master/regCTG

To return to the list of conditions and view other reports go to https://lhncbc.github.io/CRI/regCTG/regCTG-condition_report_links.html


Study Counts

Type Study_count
Total_Studies 180
interventional 171
Observational 7
Registry 2

Studies over Time by Start Date

```

Interventional Trials

Intervention Type

intervention_type Study_Count
Drug 58
Drug|Other 26
Biological|Drug|Other 12
Biological|Other 9
Biological|Drug 7
Biological|Drug|Procedure|Radiation 6
Drug|Other|Procedure|Radiation 5
Biological 4
Biological|Drug|Other|Procedure|Radiation 4
Biological|Other|Procedure 4
Drug|Procedure|Radiation 4
Biological|Drug|Radiation 3
Drug|Genetic|Other 3
Drug|Other|Procedure 3
Drug|Procedure 3
Biological|Drug|Other|Procedure 2
Drug|Radiation 2
Biological|Device|Drug|Procedure|Radiation 1
Biological|Dietary Supplement|placebo 1
Biological|Drug|Genetic|Other 1
Biological|Drug|Genetic|Other|Procedure 1
Biological|Genetic|Other 1
Biological|Genetic|Other|Procedure 1
Biological|Procedure|Radiation 1
Device|Procedure 1
Dietary Supplement|Other 1
Drug|Genetic|Other|Procedure|Radiation 1
Drug|Genetic|Procedure|Radiation 1
Drug|placebo 1
Drug|placebo|Procedure 1
Other 1
Other|Procedure 1
Radiation 1

Count of Studies by Intervention (normalized and mapped)

Interventions over Time

Yearly studies for each intervention by start date

Studies by Country

Country Study_Count
United States 118
China 5
Germany 4
Korea, Republic of 4
United States|Italy 4
Austria 3
United States|Germany|Italy 3
France 2
Taiwan 2
United States|Canada 2
Austria|Germany 1
Austria|Italy|Spain 1
Austria|Italy|Switzerland 1
Belgium|France|Italy|Portugal|Switzerland 1
Belgium|France|Italy|Spain|Switzerland|United Kingdom 1
Canada 1
Colombia|India|Russian Federation|South Africa|Ukraine 1
France|Italy 1
France|Italy|Switzerland 1
France|United States|Australia|Belgium|Denmark|Germany|Israel|Italy|Poland|Spain|United Kingdom 1
France|United States|Belgium|Germany|United Kingdom 1
Italy 1
Korea, Republic of|Singapore 1
NA 1
Poland 1
Spain 1
Switzerland 1
United States|Australia|China|Czechia|France|Italy|Korea, Republic of|New Zealand|United Kingdom 1
United States|Australia|France|Poland 1
United States|Denmark|Germany 1
United States|France 1
United States|France|Germany|Italy|Poland|United Kingdom 1
United States|Germany 1
United States|Switzerland 1

Sites per Study

Site_count Study_Count
1 98
2 16
3 4
4 4
5 6
6 3
7 6
8 1
10 3
11 7
12 1
13 2
17 1
19 2
20 3
22 2
23 1
25 3
30 1
36 1
38 1
39 1
41 1
62 1
75 1
87 1

Phase

Phase Study_Count
Phase 2 76
Phase 1 49
Phase 1/Phase 2 19
N/A 14
Phase 3 9
Early Phase 1 4

Number of Arms

Number_of_Arms Count_of_Studies
1 134
2 24
3 5
4 1
7 1
10 1
11 1
NA 4

Enrollment Metrics by Phase

Measure Early.Phase.1 N.A Phase.1 Phase.1.Phase.2 Phase.2 Phase.3
Min. 16.00 5.00000 2.00000 9.00000 5.00000 138.0000
1st Qu. 22.00 33.50000 20.00000 29.50000 33.00000 210.0000
Median 27.00 58.50000 36.00000 38.00000 50.00000 414.0000
Mean 25.75 73.14286 45.85714 69.63158 62.30263 533.1111
3rd Qu. 30.75 79.75000 60.00000 65.00000 77.75000 549.0000
Max. 33.00 200.00000 177.00000 403.00000 210.00000 1337.0000

Trial Group Type

group_type Group_Count
Experimental 211
Active Comparator 11
NA 4
No Intervention 2
Other 2
Placebo Comparator 2
Sham Comparator 1

Intervention Model

intervention_model Study_Count
Single Group Assignment 140
Parallel Assignment 25
Sequential Assignment 5
Factorial Assignment 1

Primary Purpose

primary_purpose Study_Count
Treatment 159
Supportive Care 9
Basic Science 2
Diagnostic 1

Observational Studies

Studies by Country

Country Study_Count
Japan 2
Switzerland 2
United States 2
NA 1

Sites per Study

Site_count Study_Count
1 6
42 1

Enrollment Metrics

Measure Observational
Min 20.0000
1st Qu 130.5000
Median 300.0000
Mean 284.4286
3rd Qu 425.0000
Max 560.0000

Observation Model

observational_model Study_Count
Cohort 4
Case-Only 1
Other 1
NA 1

Time Perspective

time_perspective Study_Count
Prospective 3
Retrospective 2
Other 1
NA 1

Registries

Studies by Country

Country Study_Count
Korea, Republic of 1
Spain 1

Sites per Study

Site_count Study_Count
1 1
14 1

Enrollment Metrics

Measure Registries
Min 500
1st Qu 875
Median 1250
Mean 1250
3rd Qu 1625
Max 2000

Registry Model

observational_model Study_Count
Cohort 2

Time Perspective

time_perspective Study_Count
Prospective 2

Follow-up

target_duration Study_Count
10 Years 1
5 Years 1

Overview of Studies

Interventional Trials

#If less then 500 trials

nct_id brief_title link overall_status source primary_completion_date
NCT03322865 Obinutuzumab in Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT03322865 Recruiting University of Ulm 2020-10-02
NCT03314974 Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders https://ClinicalTrials.gov/show/NCT03314974 Recruiting Masonic Cancer Center, University of Minnesota 2025-01-10
NCT03277729 A Phase I/II Study to Evaluate the Safety of Cellular Immunotherapy Using Autologous T Cells Engineered to Express a CD20-Specific Chimeric Antigen Receptor for Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT03277729 Recruiting Fred Hutchinson Cancer Research Center 2022-11-16
NCT03276468 Evaluation of Atezolizumab-Venetoclax-Obinutuzumab Combination in Relapse/Refractory Lymphomas https://ClinicalTrials.gov/show/NCT03276468 Recruiting The Lymphoma Academic Research Organisation 2019-09-19
NCT03162536 A Study of ARQ 531 in Patients With Selected Hematologic Malignancies https://ClinicalTrials.gov/show/NCT03162536 Recruiting ArQule 2021-12-31
NCT03144674 A Study of INCB050465 in Subjects With Relapsed or Refractory Marginal Zone Lymphoma (CITADEL-204) https://ClinicalTrials.gov/show/NCT03144674 Active, not recruiting Incyte Corporation 2021-01-31
NCT03105336 A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03105336 Recruiting Gilead Sciences 2022-02-28
NCT03093831 Phase II Study of Ibrutinib in Patients With Relapsed or Refractory Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT03093831 Recruiting National Cancer Centre, Singapore 2020-01-31
NCT03078855 A Study to Evaluate the Effect of Vitamin D on PFS in Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT03078855 Recruiting University of Rochester 2023-09-30
NCT03037645 Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers https://ClinicalTrials.gov/show/NCT03037645 Recruiting Sunesis Pharmaceuticals 2020-12-31
NCT03031483 Clarithromycin + Lenalidomide Combination: a Full Oral Treatment for Patients With Relapsed/Refractory Extranodal Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT03031483 Active, not recruiting International Extranodal Lymphoma Study Group (IELSG) 2021-02-28
NCT02914938 A Study of ME-401 in Subjects With CLL/SLL, FL, and B-cell Non Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT02914938 Recruiting MEI Pharma, Inc. 2021-09-30
NCT02853370 Bendamustine and Rituximab for the Treatment of Splenic Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT02853370 Active, not recruiting International Extranodal Lymphoma Study Group (IELSG) 2020-09-30
NCT02722668 UCB Transplant for Hematological Diseases Using a Non Myeloablative Prep https://ClinicalTrials.gov/show/NCT02722668 Recruiting Masonic Cancer Center, University of Minnesota 2028-05-31
NCT02652715 Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02652715 Completed Mayo Clinic 2018-12-21
NCT02927964 TLR9 Agonist SD-101, Ibrutinib, and Radiation Therapy in Treating Patients With Relapsed or Refractory Grade 1-3A Follicular Lymphoma https://ClinicalTrials.gov/show/NCT02927964 Recruiting Stanford University 2021-11-30
NCT02568553 Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02568553 Recruiting National Cancer Institute (NCI) 2020-12-31
NCT02532257 Ibrutinib in Combination With Rituximab and Lenalidomide in Treating Patients With Previously Untreated, Stage II-IV Follicular Lymphoma or Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT02532257 Active, not recruiting M.D. Anderson Cancer Center 2020-04-01
NCT02494700 Ultra Low Dose Orbital Radiation Therapy in Treating Patients With Stage I-IV Indolent B-cell Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT02494700 Recruiting M.D. Anderson Cancer Center 2021-10-31
NCT02433795 Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL) https://ClinicalTrials.gov/show/NCT02433795 Completed Seoul National University Hospital 2019-10-31
NCT02339922 Ixazomib Citrate and Rituximab in Treating Patients With Indolent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT02339922 Active, not recruiting University of Washington 2025-01-06
NCT02332980 Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT02332980 Recruiting Mayo Clinic 2021-01-05
NCT02257242 Vincristine Sulfate Liposome Injection (Marqibo®), Bendamustine and Rituximab—Phase I Trial in Indolent B-cell Lymphoma https://ClinicalTrials.gov/show/NCT02257242 Recruiting Brown University 2020-12-31
NCT02254772 A Phase I/II Study of Intratumoral Injection of SD-101 https://ClinicalTrials.gov/show/NCT02254772 Completed Stanford University 2016-11-10
NCT02213913 Lenalidomide and Combination Chemotherapy (DA-EPOCH-R) in Treating Patients With MYC-Associated B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT02213913 Recruiting University of Chicago 2020-07-29
NCT01306643 Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma https://ClinicalTrials.gov/show/NCT01306643 Completed Gilead Sciences 2015-08-31
NCT01282424 Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT01282424 Completed Gilead Sciences 2018-05-02
NCT01273766 Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01273766 Completed Wake Forest University Health Sciences 2012-03-31
NCT02049541 Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma https://ClinicalTrials.gov/show/NCT02049541 Active, not recruiting Ohio State University Comprehensive Cancer Center 2018-09-12
NCT03479268 Pevonedistat and Ibrutinib in Treating Participants With Relapsed or Refractory CLL or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03479268 Recruiting City of Hope Medical Center 2022-04-01
NCT01995669 Lenalidomide and Obinutuzumab in Treating Patients With Relapsed Indolent Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01995669 Active, not recruiting M.D. Anderson Cancer Center 2021-05-31
NCT01980628 Study of the Bruton’s Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT01980628 Completed Pharmacyclics LLC. 2016-07-31
NCT01962636 Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases https://ClinicalTrials.gov/show/NCT01962636 Recruiting Masonic Cancer Center, University of Minnesota 2023-10-31
NCT01959477 Dose Monitoring of Busulfan and Combination Chemotherapy in Hodgkin or Non-Hodgkin Lymphoma Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01959477 Completed Case Comprehensive Cancer Center 2015-01-31
NCT01820910 Phase II Trial of First-line Doxycycline for Ocular Adnexal Marginal Zone Lymphoma Treatment https://ClinicalTrials.gov/show/NCT01820910 Active, not recruiting International Extranodal Lymphoma Study Group (IELSG) 2016-05-31
NCT01815749 Genetically Modified T-cell Infusion Following Peripheral Blood Stem Cell Transplant in Treating Patients With Recurrent or High-Risk Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01815749 Active, not recruiting City of Hope Medical Center 2020-10-31
NCT01808599 Phase II Study of Chlorambucil and Subcutaneous Rituximab in Patients With Extranodal MALT Lymphoma https://ClinicalTrials.gov/show/NCT01808599 Active, not recruiting International Extranodal Lymphoma Study Group (IELSG) 2016-03-31
NCT01805037 Brentuximab Vedotin + Rituximab as Frontline Therapy for Pts w/ CD30+ and/or EBV+ Lymphomas https://ClinicalTrials.gov/show/NCT01805037 Active, not recruiting Northwestern University 2021-01-31
NCT01789255 Vorinostat, Tacrolimus, and Methotrexate in Preventing GVHD After Stem Cell Transplant in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01789255 Completed National Cancer Institute (NCI) 2014-03-31
NCT01760655 Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01760655 Recruiting Thomas Jefferson University 2021-03-31
NCT01748721 MORAb-004 in Treating Young Patients With Recurrent or Refractory Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT01748721 Completed Morphotek 2015-05-31
NCT01701232 Safety and Efficacy Study of BCD-020 in Therapy of Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01701232 Completed Biocad 2017-01-31
NCT01682044 Pegfilgrastim and Rituximab in Treating Patients With Untreated, Relapsed, or Refractory Follicular Lymphoma, Small Lymphocytic Lymphoma, or Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT01682044 Completed Roswell Park Cancer Institute 2013-11-22
NCT01678443 Monoclonal Antibody Therapy Before Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT01678443 Active, not recruiting Fred Hutchinson Cancer Research Center 2011-04-11
NCT01658319 Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01658319 Completed Case Comprehensive Cancer Center 2015-02-28
NCT01588015 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01588015 Active, not recruiting City of Hope Medical Center 2021-11-30
NCT01583699 Endomicroscopy and Gastric MALT-lymphoma https://ClinicalTrials.gov/show/NCT01583699 Completed Medical University of Vienna 2014-03-31
NCT01567709 Alisertib in Combination With Vorinostat in Treating Patients With Relapsed or Recurrent Hodgkin Lymphoma, B-Cell Non-Hodgkin Lymphoma, or Peripheral T-Cell Lymphoma https://ClinicalTrials.gov/show/NCT01567709 Completed National Cancer Institute (NCI) 2018-03-29
NCT01529827 Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01529827 Completed Roswell Park Cancer Institute 2015-05-28
NCT01523223 Donor Peripheral Stem Cell Transplant in Treating Patients With Hematolymphoid Malignancies https://ClinicalTrials.gov/show/NCT01523223 Completed Stanford University 2016-09-30
NCT01484015 Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia https://ClinicalTrials.gov/show/NCT01484015 Completed Wake Forest University Health Sciences 2012-06-30
NCT01479842 Rituxan/Bendamustine/PCI-32765 in Relapsed DLBCL, MCL, or Indolent Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT01479842 Active, not recruiting Ohio State University Comprehensive Cancer Center 2014-03-31
NCT01460134 A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers https://ClinicalTrials.gov/show/NCT01460134 Completed Celldex Therapeutics 2015-12-31
NCT01427881 Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01427881 Completed Fred Hutchinson Cancer Research Center 2014-06-30
NCT01427114 R-CVP for the Treatment of Non-conjunctival Ocular Adnexal MALT Lymphoma (OAML) https://ClinicalTrials.gov/show/NCT01427114 Active, not recruiting Konkuk University Medical Center 2014-08-01
NCT01384513 A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT01384513 Recruiting Thomas Jefferson University 2020-12-31
NCT01326702 Veliparib, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory Lymphoma, Multiple Myeloma, or Solid Tumors https://ClinicalTrials.gov/show/NCT01326702 Completed National Cancer Institute (NCI) 2015-04-30
NCT04433156 VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT04433156 Recruiting Henan Cancer Hospital 2022-04-22
NCT04323956 Parsaclisib Plus the Standard Drug Therapy in Patients With Newly Diagnosed, High Risk Diffuse Large B-cell Lymphoma https://ClinicalTrials.gov/show/NCT04323956 Recruiting Mayo Clinic 2026-05-15
NCT04212013 A Study of Ibrutinib With Rituximab in People With Untreated Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT04212013 Recruiting Memorial Sloan Kettering Cancer Center 2024-06-30
NCT04205409 Nivolumab for Relapsed or Refractory Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT04205409 Recruiting University of Washington 2022-08-01
NCT04097067 ISRT 20 Gy for Indolent Localized Gastrointestinal (GI)-Lymphoma https://ClinicalTrials.gov/show/NCT04097067 Recruiting University Hospital Muenster 2021-08-31
NCT04082936 A Safety and Pharmacokinetic Study of IGM-2323 in Subjects With Relapsed/Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT04082936 Recruiting IGM Biosciences, Inc. 2021-09-30
NCT04014205 A Study of Tyrosine Kinase Inhibitor ICP-022 in Patients With r/r B-Cell Malignancies https://ClinicalTrials.gov/show/NCT04014205 Recruiting Beijing InnoCare Pharma Tech Co., Ltd. 2020-08-17
NCT03999697 A Clinical Research of CD22-Targeted CAR-T in B Cell Malignancies https://ClinicalTrials.gov/show/NCT03999697 Recruiting PersonGen BioTherapeutics (Suzhou) Co., Ltd. 2020-12-01
NCT03919175 Umbralisib and Rituximab as Initial Therapy for Patients With Follicular Lymphoma and Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT03919175 Recruiting Massachusetts General Hospital 2022-11-30
NCT03846427 Study of Zanubrutinib (BGB-3111) in Participants With Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT03846427 Active, not recruiting BeiGene 2021-04-01
NCT03797456 A Study to Evaluate ICP-022 in Patients With R/R Marginal Zone Lymphoma (MZL) https://ClinicalTrials.gov/show/NCT03797456 Recruiting Beijing InnoCare Pharma Tech Co., Ltd. 2021-02-28
NCT03740529 A Study of Oral LOXO-305 in Patients With Previously Treated CLL/SLL or NHL https://ClinicalTrials.gov/show/NCT03740529 Recruiting Loxo Oncology, Inc. 2020-10-31
NCT03697512 MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas https://ClinicalTrials.gov/show/NCT03697512 Recruiting International Extranodal Lymphoma Study Group (IELSG) 2024-06-15
NCT03680586 Ultra Low-Dose Radiation Therapy in Treating Patients With Stage I-IV Stomach MALT Lymphoma https://ClinicalTrials.gov/show/NCT03680586 Recruiting M.D. Anderson Cancer Center 2021-05-08
NCT03583424 Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03583424 Recruiting Ohio State University Comprehensive Cancer Center 2021-12-31
NCT03498612 Pembrolizumab in Untreated B-Cell Non-Hodgkin Lymphoproliferative Diseases https://ClinicalTrials.gov/show/NCT03498612 Recruiting University of Washington 2022-09-16
NCT03474744 Copanlisib and Rituximab in Marginal Zone Lymphoma Patients https://ClinicalTrials.gov/show/NCT03474744 Recruiting University of Ulm 2028-06-01
NCT01261247 Panobinostat in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01261247 Active, not recruiting Mayo Clinic 2016-05-09
NCT01258998 Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma https://ClinicalTrials.gov/show/NCT01258998 Completed National Cancer Institute (NCI) 2014-07-31
NCT01254578 Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers https://ClinicalTrials.gov/show/NCT01254578 Completed National Cancer Institute (NCI) 2012-11-09
NCT01239875 Vaccine Therapy With or Without Cryosurgery in Treating Patients With Residual, Relapsed, or Refractory B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01239875 Completed Mayo Clinic 2015-11-24
NCT01233921 Palifermin in Preventing Chronic Graft-Versus-Host Disease in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT01233921 Completed Fred Hutchinson Cancer Research Center 2012-07-31
NCT01231919 MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia https://ClinicalTrials.gov/show/NCT01231919 Completed National Cancer Institute (NCI) 2013-04-30
NCT01213095 Rituximab Maintenance Therapy for Marginal Zone B-cell Lymphoma (MZL) https://ClinicalTrials.gov/show/NCT01213095 Completed Dong-A University Hospital 2013-09-30
NCT01177371 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01177371 Completed Case Comprehensive Cancer Center 2000-02-29
NCT01164267 Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL) https://ClinicalTrials.gov/show/NCT01164267 Completed International Extranodal Lymphoma Study Group (IELSG) 2012-12-31
NCT01158274 RO4929097 and Capecitabine in Treating Patients With Refractory Solid Tumors https://ClinicalTrials.gov/show/NCT01158274 Completed National Cancer Institute (NCI) 2012-08-31
NCT01129193 AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma https://ClinicalTrials.gov/show/NCT01129193 Completed Ohio State University Comprehensive Cancer Center 2017-01-07
NCT01110135 Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma https://ClinicalTrials.gov/show/NCT01110135 Completed University of Washington 2013-11-30
NCT01093586 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01093586 Completed Case Comprehensive Cancer Center 2015-12-31
NCT01075321 Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT01075321 Active, not recruiting Mayo Clinic 2015-02-28
NCT01068392 Oxaliplatin and Prednisolone (Ox-P) for Patients With Relapsed or Refractory Marginal Zone B-cell Lymphoma(MZL) https://ClinicalTrials.gov/show/NCT01068392 Completed Dong-A University Hospital 2013-09-30
NCT01015248 Trial of Bendamustine And Rituximab for Patients With Previously Untreated Extranodal Mucosa-Associated Lymphoid Tissue (MALT) Lymphoma https://ClinicalTrials.gov/show/NCT01015248 Completed Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 2013-12-31
NCT00991211 Bendamustine Plus Rituximab Versus CHOP Plus Rituximab https://ClinicalTrials.gov/show/NCT00991211 Completed University of Giessen 2009-08-31
NCT00918333 Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00918333 Completed Mayo Clinic 2015-12-01
NCT00891072 Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery https://ClinicalTrials.gov/show/NCT00891072 Completed National Cancer Institute (NCI) 2011-04-30
NCT00890747 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy https://ClinicalTrials.gov/show/NCT00890747 Completed National Cancer Institute (NCI) 2011-05-31
NCT00877214 Significance of Duration of Maintenance Therapy With Rituximab in Non-Hodgkin Lymphomas https://ClinicalTrials.gov/show/NCT00877214 Active, not recruiting University of Giessen 2022-04-30
NCT00867529 Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma https://ClinicalTrials.gov/show/NCT00867529 Completed Fred Hutchinson Cancer Research Center 2015-03-31
NCT00856388 Fludarabine Phosphate, Melphalan, Total-Body Irradiation, Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer or Bone Marrow Failure Disorders https://ClinicalTrials.gov/show/NCT00856388 Completed Roswell Park Cancer Institute 2012-08-09
NCT01839916 Donor T Cells After Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT01839916 Completed University of Chicago 2018-08-31
NCT00801281 First-line R-CVP vs R-CHOP Induction Immunochemotherapy for Indolent Lymphoma and R Maintenance. https://ClinicalTrials.gov/show/NCT00801281 Completed Polish Lymphoma Research Group 2017-06-25
NCT03520920 BTK Inhibitor BGB-3111 in Chinese Patients With Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL) https://ClinicalTrials.gov/show/NCT03520920 Active, not recruiting BeiGene 2020-11-30
NCT03147885 Selinexor Plus Combination Chemotherapy in Treating Patients With Advanced B Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT03147885 Recruiting Barbara Ann Karmanos Cancer Institute 2020-06-30
NCT04298879 IBI376 in Relapsed or Refractory Follicular Lymphoma/Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT04298879 Recruiting Innovent Biologics (Suzhou) Co. Ltd. 2021-07-31
NCT00783367 Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas https://ClinicalTrials.gov/show/NCT00783367 Active, not recruiting Abramson Cancer Center of the University of Pennsylvania 2012-11-14
NCT00769288 FAU in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00769288 Completed National Cancer Institute (NCI) 2013-12-31
NCT00720135 Fusion Protein Cytokine Therapy After Rituximab in Treating Patients With B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00720135 Completed City of Hope Medical Center 2014-07-31
NCT00711828 Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00711828 Completed Mayo Clinic 2013-11-30
NCT00695786 Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00695786 Active, not recruiting M.D. Anderson Cancer Center 2020-06-30
NCT00656812 Rituximab Plus 2CdA in Patients With Advanced or Relapsed Mucosa Associated Lymphoid Tissue (MALT) Lymphoma https://ClinicalTrials.gov/show/NCT00656812 Completed Arbeitsgemeinschaft medikamentoese Tumortherapie 2011-09-30
NCT00621452 Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00621452 Completed Fred Hutchinson Cancer Research Center 2014-01-31
NCT00608361 Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery https://ClinicalTrials.gov/show/NCT00608361 Completed National Cancer Institute (NCI) 2014-08-31
NCT00601718 Vorinostat, Rituximab, Ifosfamide, Carboplatin, and Etoposide in Treating Patients With Relapsed or Refractory Lymphoma or Previously Untreated T-Cell Non-Hodgkin Lymphoma or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00601718 Completed University of Washington 2010-06-30
NCT00566332 Trial Comparing Chlorambucil to Fludarabine in Patients With Advanced Waldenström Macroglobulinemia https://ClinicalTrials.gov/show/NCT00566332 Completed French Study Group on Chronic Lymphoid Leukemia 2009-09-30
NCT00536601 High-Dose Chemotherapy With or Without Total-Body Irradiation Followed by Autologous Stem Cell Transplant in Treating Patients With Hematologic Cancer or Solid Tumors https://ClinicalTrials.gov/show/NCT00536601 Completed Roswell Park Cancer Institute 2018-07-09
NCT00499811 Vorinostat in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphoma and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00499811 Completed National Cancer Institute (NCI) 2011-08-31
NCT00489203 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00489203 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00458731 Bevacizumab and Cediranib Maleate in Treating Patients With Metastatic or Unresectable Solid Tumor, Lymphoma, Intracranial Glioblastoma, Gliosarcoma or Anaplastic Astrocytoma https://ClinicalTrials.gov/show/NCT00458731 Completed National Cancer Institute (NCI) 2013-12-31
NCT00453102 Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT00453102 Completed University of Miami 2015-02-28
NCT00438880 Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00438880 Completed Mayo Clinic 2010-10-31
NCT00408681 Lithium Carbonate in Treating Patients With Acute Intestinal Graft-Versus-Host-Disease (GVHD) After Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00408681 Completed Fred Hutchinson Cancer Research Center 2010-11-30
NCT00799461 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications https://ClinicalTrials.gov/show/NCT00799461 Completed Fred Hutchinson Cancer Research Center 2011-11-30
NCT00373906 Velcade in MALT Lymphoma Patients https://ClinicalTrials.gov/show/NCT00373906 Completed Medical University of Vienna NA
NCT00373646 Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients https://ClinicalTrials.gov/show/NCT00373646 Completed Medical University of Vienna 2009-01-31
NCT00348985 PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00348985 Completed National Cancer Institute (NCI) 2010-01-31
NCT00343798 A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00343798 Completed Fred Hutchinson Cancer Research Center 2013-07-31
NCT00327132 Prospective Study of First-line Antibiotic Therapy for Early-stage Gastric MALT Lymphoma for Treatment Outcome https://ClinicalTrials.gov/show/NCT00327132 Completed National Health Research Institutes, Taiwan 2015-12-31
NCT00293345 3-AP and Gemcitabine in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00293345 Completed National Cancer Institute (NCI) 2012-10-31
NCT00290472 CCI-779 in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00290472 Completed National Cancer Institute (NCI) 2010-04-30
NCT00275080 Vorinostat and Decitabine in Treating Patients With Advanced Solid Tumors or Relapsed or Refractory Non-Hodgkin’s Lymphoma, Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, or Chronic Myelogenous Leukemia https://ClinicalTrials.gov/show/NCT00275080 Completed National Cancer Institute (NCI) 2009-11-30
NCT00253630 Vorinostat in Treating Patients With Low-Grade Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00253630 Completed National Cancer Institute (NCI) 2016-05-31
NCT00244855 Rituximab and Dexamethasone in Treating Patients With Low-Grade Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00244855 Completed Fred Hutchinson Cancer Research Center 2008-12-31
NCT00210353 Randomized Trial of Chlorambucil Versus Chlorambucil Plus Rituximab Versus Rituximab in MALT Lymphoma https://ClinicalTrials.gov/show/NCT00210353 Completed International Extranodal Lymphoma Study Group (IELSG) 2015-04-30
NCT00210327 VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy https://ClinicalTrials.gov/show/NCT00210327 Completed International Extranodal Lymphoma Study Group (IELSG) 2008-11-30
NCT00201422 Eradication of Helicobacter Pylori in the Management of Stage IE & IIE-1 Primary Low-grade B Cell Lymphoma of MALToma https://ClinicalTrials.gov/show/NCT00201422 Completed National Health Research Institutes, Taiwan 2004-01-31
NCT00119392 Yttrium Y 90 Ibritumomab Tiuxetan, Fludarabine, Radiation Therapy, and Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00119392 Completed Fred Hutchinson Cancer Research Center 2009-07-31
NCT00118352 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00118352 Completed Fred Hutchinson Cancer Research Center 2010-07-31
NCT00118170 Sorafenib in Treating Patients With Metastatic or Unresectable Solid Tumors, Multiple Myeloma, or Non-Hodgkin’s Lymphoma With or Without Impaired Liver or Kidney Function https://ClinicalTrials.gov/show/NCT00118170 Completed National Cancer Institute (NCI) 2007-05-31
NCT00117156 Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00117156 Completed Dana-Farber Cancer Institute 2008-10-31
NCT00112593 Fludarabine and Total-Body Irradiation Followed By Donor Stem Cell Transplant and Cyclosporine and Mycophenolate Mofetil in Treating HIV-Positive Patients With or Without Cancer https://ClinicalTrials.gov/show/NCT00112593 Completed Fred Hutchinson Cancer Research Center 2014-11-30
NCT00110071 Iodine I 131 Tositumomab and Fludarabine Phosphate in Treating Older Patients Who Are Undergoing an Autologous or Syngeneic Stem Cell Transplant for Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00110071 Completed Fred Hutchinson Cancer Research Center 2011-06-30
NCT00105001 Tacrolimus and Mycophenolate Mofetil With or Without Sirolimus in Preventing Acute Graft-Versus-Host Disease in Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00105001 Completed Fred Hutchinson Cancer Research Center 2011-05-31
NCT00098891 MS-275 and Isotretinoin in Treating Patients With Metastatic or Advanced Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00098891 Completed National Cancer Institute (NCI) 2008-03-31
NCT00089271 17-DMAG in Treating Patients With Metastatic or Unresectable Solid Tumors or Lymphomas https://ClinicalTrials.gov/show/NCT00089271 Completed National Cancer Institute (NCI) 2010-06-30
NCT00089011 Tacrolimus and Mycophenolate Mofetil in Preventing Graft-Versus-Host Disease in Patients Who Have Undergone Total-Body Irradiation With or Without Fludarabine Phosphate Followed by Donor Peripheral Blood Stem Cell Transplant for Hematologic Cancer https://ClinicalTrials.gov/show/NCT00089011 Completed Fred Hutchinson Cancer Research Center 2014-03-31
NCT00003196 Low-Dose Total Body Irradiation and Donor Peripheral Blood Stem Cell Transplant Followed by Donor Lymphocyte Infusion in Treating Patients With Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma https://ClinicalTrials.gov/show/NCT00003196 Completed Fred Hutchinson Cancer Research Center 2002-04-30
NCT00002682 Antibiotic Therapy and Antacids in Patients With Malt Lymphoma of the Stomach https://ClinicalTrials.gov/show/NCT00002682 Completed M.D. Anderson Cancer Center 2001-10-08
NCT00006251 Fludarabine Phosphate, Low-Dose Total-Body Irradiation, and Donor Stem Cell Transplant Followed by Cyclosporine, Mycophenolate Mofetil, Donor Lymphocyte Infusion in Treating Patients With Hematopoietic Cancer https://ClinicalTrials.gov/show/NCT00006251 Completed Fred Hutchinson Cancer Research Center 2005-09-30
NCT00082888 Tipifarnib in Treating Patients With Relapsed or Refractory Lymphoma https://ClinicalTrials.gov/show/NCT00082888 Completed National Cancer Institute (NCI) 2009-05-20
NCT00082784 Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms https://ClinicalTrials.gov/show/NCT00082784 Completed National Cancer Institute (NCI) 2012-10-31
NCT00005799 Fludarabine Phosphate, Low-Dose Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Hematologic Malignancies or Kidney Cancer https://ClinicalTrials.gov/show/NCT00005799 Completed Fred Hutchinson Cancer Research Center 2002-07-31
NCT00078858 Mycophenolate Mofetil and Cyclosporine in Reducing Graft-Versus-Host Disease in Patients With Hematologic Malignancies or Metastatic Kidney Cancer Undergoing Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00078858 Completed Fred Hutchinson Cancer Research Center 2006-01-31
NCT00077155 Cilengitide (EMD 121974) in Treating Patients With Advanced Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00077155 Completed National Cancer Institute (NCI) 2010-06-30
NCT00073918 Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00073918 Completed Fred Hutchinson Cancer Research Center 2011-10-02
NCT00072514 Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies https://ClinicalTrials.gov/show/NCT00072514 Completed Fred Hutchinson Cancer Research Center 2008-07-31
NCT00068315 Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin’s Lymphoma or Chronic Lymphocytic Leukemia https://ClinicalTrials.gov/show/NCT00068315 Completed National Cancer Institute (NCI) 2008-12-31
NCT00003210 Interleukin-12 in Treating Patients With Previously Treated Non-Hodgkin’s Lymphoma or Hodgkin’s Disease https://ClinicalTrials.gov/show/NCT00003210 Completed National Cancer Institute (NCI) 2003-11-30
NCT00058305 Bryostatin 1 Plus Vincristine in Treating Patients With Progressive or Relapsed Non-Hodgkin’s Lymphoma After Bone Marrow or Stem Cell Transplantation https://ClinicalTrials.gov/show/NCT00058305 Completed National Cancer Institute (NCI) 2007-12-31
NCT00058227 Alvocidib, Fludarabine Phosphate, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma https://ClinicalTrials.gov/show/NCT00058227 Completed National Cancer Institute (NCI) 2009-02-28
NCT00054639 Oblimersen Sodium and Rituximab in Treating Patients With Recurrent B-cell Non-Hodgkin Lymphoma https://ClinicalTrials.gov/show/NCT00054639 Completed National Cancer Institute (NCI) 2010-01-31
NCT00054483 Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction https://ClinicalTrials.gov/show/NCT00054483 Completed National Cancer Institute (NCI) 2009-09-30
NCT00049504 Haploidentical Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancer https://ClinicalTrials.gov/show/NCT00049504 Completed Fred Hutchinson Cancer Research Center 2011-03-31
NCT00040846 Alemtuzumab, Fludarabine Phosphate, and Low-Dose Total Body Irradiation Before Donor Stem Cell Transplantation in Treating Patients With Hematological Malignancies https://ClinicalTrials.gov/show/NCT00040846 Completed Fred Hutchinson Cancer Research Center 2009-12-31
NCT00795769 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant https://ClinicalTrials.gov/show/NCT00795769 Completed Fred Hutchinson Cancer Research Center 2009-06-09
NCT00026182 Rituximab and Interleukin-12 in Treating Patients With B-Cell Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00026182 Completed National Cancer Institute (NCI) 2005-02-28
NCT00025415 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction https://ClinicalTrials.gov/show/NCT00025415 Completed National Cancer Institute (NCI) 2005-01-31
NCT00017472 Monoclonal Antibody Therapy in Treating Patients With Chronic Lymphocytic Leukemia, Lymphocytic Lymphoma, Acute Lymphoblastic Leukemia, or Acute Myeloid Leukemia https://ClinicalTrials.gov/show/NCT00017472 Completed National Cancer Institute (NCI) 2006-04-30
NCT00017381 Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00017381 Completed National Cancer Institute (NCI) 2007-12-31
NCT00014235 Fludarabine Phosphate and Total-Body Radiation Followed by Donor Peripheral Blood Stem Cell Transplant and Immunosuppression in Treating Patients With Hematologic Malignancies https://ClinicalTrials.gov/show/NCT00014235 Completed Fred Hutchinson Cancer Research Center 2005-02-28
NCT00010192 Rituximab Plus Interleukin-2 in Treating Patients With Hematologic Cancer https://ClinicalTrials.gov/show/NCT00010192 Completed National Cancer Institute (NCI) 2003-01-31
NCT00006473 Oxaliplatin in Treating Patients With Relapsed or Refractory Non-Hodgkin’s Lymphoma https://ClinicalTrials.gov/show/NCT00006473 Completed National Cancer Institute (NCI) 2006-02-28
NCT00004241 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Advanced Epithelial Cancer, Malignant Lymphoma, or Sarcoma https://ClinicalTrials.gov/show/NCT00004241 Completed National Cancer Institute (NCI) 2006-05-31
NCT00003970 Genetic Testing Plus Irinotecan in Treating Patients With Solid Tumors or Lymphoma https://ClinicalTrials.gov/show/NCT00003970 Completed National Cancer Institute (NCI) 2003-10-31

Observational Studiess

#If less then 500 studies

nct_id brief_title link overall_status source primary_completion_date
NCT03288415 SMZL Molecular Prognostic Index https://ClinicalTrials.gov/show/NCT03288415 Active, not recruiting Oncology Institute of Southern Switzerland 2020-06-30
NCT03219723 Drug Use Surveillance of Takecab for “Supplement to Helicobacter Pylori Eradication” https://ClinicalTrials.gov/show/NCT03219723 Completed Takeda 2017-04-30
NCT02945319 Integrated Molecular and Clinical Profiling to Optimize Outcome Prediction in Splenic Marginal Zone Lymphoma https://ClinicalTrials.gov/show/NCT02945319 Active, not recruiting International Extranodal Lymphoma Study Group (IELSG) 2020-06-30
NCT01720758 Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease https://ClinicalTrials.gov/show/NCT01720758 Completed HaEmek Medical Center, Israel 2013-03-31
NCT01264822 Prognostic Study of Gastric MALT Lymphoma After Eradication of Helicobacter Pylori https://ClinicalTrials.gov/show/NCT01264822 Completed Eisai Inc. 2016-02-29
NCT01199562 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant https://ClinicalTrials.gov/show/NCT01199562 Completed City of Hope Medical Center 2013-12-31
NCT00923507 Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL) https://ClinicalTrials.gov/show/NCT00923507 Recruiting National Institutes of Health Clinical Center (CC) NA

Registries

#If less then 500 registries

nct_id brief_title link overall_status source primary_completion_date
NCT02732236 Marginal Zone Lymphoma Cohort in Korea https://ClinicalTrials.gov/show/NCT02732236 Recruiting Dong-A University Hospital 2020-02-29
NCT03646422 AEDV Registry of Primary Cutaneous Lymphoma https://ClinicalTrials.gov/show/NCT03646422 Recruiting Fundación Academia Española de Dermatología 2025-01-01